Biopharmaceutical company Mabwell (迈威生物) plans to raise up to HK$1.45 billion ($185 million) in its Hong Kong initial public offering, with shares set to begin trading on April 28.
According to a filing from Livermore Securities, the company is offering 47.13 million shares on the exchange's Main Board.
The shares are being marketed at a maximum price of HK$30.71 each. The proposed ticker for the company has not yet been disclosed. Details regarding cornerstone investors or potential oversubscription were not included in the initial filing.
The IPO will provide Mabwell with significant capital for research, development, and expansion. The trading debut will serve as an indicator of investor appetite for biotech listings on the Hong Kong exchange and could impact sector sentiment.
This article is for informational purposes only and does not constitute investment advice.
